Sector: health
Conviction from: NASDAQ
52-week range: 48.7893.42
BridgeBio Pharma develops medicines for genetic diseases and cancers, advancing a pipeline of targeted therapies across multiple rare-disease programs.
4 tracked filer(s) hold this · 1 opened, 3 added, 0 trimmed in 30-JUN-2026
Aggregate 13FScore 62 — mean of 4 scored holder(s) · buyers (new/add) avg 62. Higher = the smart money in this name has the better track record.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|
| Louis Bacon / Moore | 53 | New buy | 31,930,000 | $56,880,957 | 0.8% |
| Steve Cohen / Point72 | 76 | Added +3147% | 1,532,782 | $114,161,603 | 0.1% |
| Bridgewater | 56 | Added +73% | 448,143 | $33,377,691 | 0.1% |
| Paul Tudor Jones / Tudor | 63 | Added +288% | 109,670 | $8,168,222 | 0.0% |
Beyond 13F — activists, insiders, politicians & research
| Filed | Form | Activist | % of class | Conviction | |
|---|
| 2026-04-02 | SCHEDULE 13D/A | VIKING GLOBAL INVESTORS LP | 6.1% | Med | filing |
| 2026-02-17 | SCHEDULE 13D/A | VIKING GLOBAL INVESTORS LP | 6.8% | Med | filing |
5 disclosed trade(s) by 1 filer(s).
| Trade date | Who | Type | Amount | |
|---|
| 2026-05-11 | Gilbert Cisneros CA31 | BUY | $1,001 - $15,000 | PTR |
| 2026-04-29 | Gilbert Cisneros CA31 | BUY | $1,001 - $15,000 | PTR |
| 2026-03-19 | Gilbert Cisneros CA31 | BUY | $1,001 - $15,000 | PTR |
| 2026-03-18 | Gilbert Cisneros CA31 | BUY | $1,001 - $15,000 | PTR |
| 2026-03-03 | Gilbert Cisneros CA31 | BUY | $1,001 - $15,000 | PTR |
1 disclosed trade(s) by 1 filer(s).